Cargando…
On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2
A new betacoronavirus named SARS-CoV-2 has emerged as a new threat to global health and economy. A promising target for both diagnosis and therapeutics treatments of the new disease named COVID-19 is the coronavirus (CoV) spike (S) glycoprotein. By constant-pH Monte Carlo simulations and the PROCEED...
Autores principales: | Corrêa Giron, Carolina, Laaksonen, Aatto, Barroso da Silva, Fernando L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228703/ https://www.ncbi.nlm.nih.gov/pubmed/32416259 http://dx.doi.org/10.1016/j.virusres.2020.198021 |
Ejemplares similares
-
Towards an optimal monoclonal antibody with higher binding affinity to the receptor-binding domain of SARS-CoV-2 spike proteins from different variants
por: Neamtu, Andrei, et al.
Publicado: (2023) -
Up State of the SARS-COV-2 Spike Homotrimer Favors an Increased Virulence for New Variants
por: Giron, Carolina Corrêa, et al.
Publicado: (2021) -
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
por: Ge, Shuai, et al.
Publicado: (2021) -
Structural insights into the binding of SARS-CoV-2, SARS-CoV, and hCoV-NL63 spike receptor-binding domain to horse ACE2
por: Lan, Jun, et al.
Publicado: (2022) -
Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor
por: Zhao, Peng, et al.
Publicado: (2020)